Deborah Toppmeyer, M.D., Co-Principal Investigator of STAR at CINJ and Director of the New Jersey Comprehensive Breast Care Center of Robert Wood Johnson University Hospital and CINJ, said, We are pleased that we can now give New Jersey women who are at high risk for developing breast cancer another option through this promising protocol.
All participants receive one or the other drug for five years.
Mary Todd, D.O., Deputy Director of The Cancer Institute of New Jersey said, Through the New Jersey Comprehensive Breast Care Center and CINJ's statewide network of 17 partner and affiliate institutions, eligible women now have access to this trial throughout New Jersey. STAR is supported by the National Cancer Institute. However, these drugs have not been compared to each other to determine which one is more effective and has less side-effects. Both tamoxifen and raloxifene have known side effects. All women interested in participating will be fully informed of the benefits and potential risks of these drugs.